QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 28 September 2005
doi: 10.1242/dev.02048

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: dev.02048v1 132/21/4883    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takaesu, N. T. Articles by Newfeld, S. J. Search for Related Content PubMed PubMed Citation Articles by Takaesu, N. T. Articles by Newfeld, S. J.

DNA-binding domain mutations in SMAD genes yield dominant-negative proteins or a neomorphic protein that can activate WG target genes in Drosophila

Norma T. Takaesu¹, Eric Herbig^1,*, David Zhitomersky², Michael B. O'Connor² and Stuart J. Newfeld^1,

¹ School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA
² Howard Hughes Medical Institute, Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA

Author for correspondence (e-mail: newfeld{at}asu.edu)

Accepted 18 August 2005

Mutations in SMAD tumor suppressor genes are involved in approximately 140,000 new cancers in the USA each year. At this time, how the absence of a functional SMAD protein leads to a tumor is unknown. However, clinical and biochemical studies suggest that all SMAD mutations are loss-of-function mutations. One prediction of this hypothesis is that all SMAD mutations cause tumors via a single mechanism. To test this hypothesis, we expressed five tumor-derived alleles of human SMAD genes and five mutant alleles of Drosophila SMAD genes in flies. We found that all of the DNA-binding domain mutations conferred gain-of-function activity, thereby falsifying the hypothesis. Furthermore, two types of gain-of-function mutation were identified – dominant negative and neomorphic. In numerous assays, the neomorphic allele SMAD4^100T appears to be capable of activating the expression of WG target genes. These results imply that SMAD4^100T may induce tumor formation by a fundamentally different mechanism from other SMAD mutations, perhaps via the ectopic expression of WNT target genes – an oncogenic mechanism associated with mutations in Adenomatous Polyposis Coli. Our results are likely to have clinical implications, because gain-of-function mutations may cause tumors when heterozygous, and the life expectancy of individuals with SMAD4^100T is likely to be different from those with other SMAD mutations. From a larger perspective, our study shows that the genetic characterization of missense mutations, particularly in modular proteins, requires experimental verification.

Key words: Drosophila, SMAD genes, TGFß, Tumorigenesis, Pancreatic cancer, Colon cancer

This article has been cited by other articles:

				S. K. Lim and F. M. Hoffmann Smad4 cooperates with lymphoid enhancer-binding factor 1/T cell-specific factor to increase c-myc expression in the absence of TGF-beta signaling PNAS, December 5, 2006; 103(49): 18580 - 18585. [Abstract] [Full Text] [PDF]

				N. T. Takaesu, C. Hyman-Walsh, Y. Ye, R. G. Wisotzkey, M. J. Stinchfield, M. B. O'Connor, D. Wotton, and S. J. Newfeld dSno Facilitates Baboon Signaling in the Drosophila Brain by Switching the Affinity of Medea Away From Mad and Toward dSmad2 Genetics, November 1, 2006; 174(3): 1299 - 1313. [Abstract] [Full Text] [PDF]